Immunaeon provides cellular preservation and long-term cryogenic storage services for individuals, families, and patients seeking to bank healthy immune cells for future use. The company guides clients through a consultation, collection, processing, and storage process, offering informational health analyses without providing direct medical treatment or diagnosis.
Subscribe to see Immunaeon Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Immunaeon Inc. is a biotechnology & healthcare company headquartered in Buffalo, United States. Its most recent funding round raised $250,000 in February 2023. Xcout tracks 6 named people at Immunaeon Inc., including Adam Utley (Co-Founder & CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Immunaeon Inc.'s closest competitors — see the full list of competitors and alternatives →
Teiko provides cytometry products and services designed for global clinical trials, including blood preservation kits, CLIA-validated spectral flow and mass cytometry panels, and data reporting dashboards. The company serves pharmaceutical and clinical research organizations by facilitating immune cell profiling and statistical analysis.
ImmunoProfile provides an at-home diagnostic testing system that evaluates an individual's antibody levels for eleven common, vaccine-preventable infectious diseases using a finger-prick blood sample. The company serves families, healthcare workers, students, travelers, and employers seeking to assess immunity status and identify potential gaps in protection.
Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.
Gene Solutions LLC provides AI-powered genetic testing and multi-dimensional genomics services focused on oncology and reproductive health. The company offers blood-based early cancer detection tests, tumor profiling, and minimal residual disease monitoring for patients and healthcare providers.
Savicell Corp develops blood test technology, specifically the Well-Shield platform, designed for the early detection of diseases with a primary focus on cancer. The technology detects and interprets immune system metabolic responses to cell malformation and disease intrusion.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Immunaeon Inc.? Suggest a correction · Work at Immunaeon Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.